AU2001230588A1 - Preventive or therapeutic agents for gastric or esophageal regurgitation - Google Patents

Preventive or therapeutic agents for gastric or esophageal regurgitation

Info

Publication number
AU2001230588A1
AU2001230588A1 AU2001230588A AU3058801A AU2001230588A1 AU 2001230588 A1 AU2001230588 A1 AU 2001230588A1 AU 2001230588 A AU2001230588 A AU 2001230588A AU 3058801 A AU3058801 A AU 3058801A AU 2001230588 A1 AU2001230588 A1 AU 2001230588A1
Authority
AU
Australia
Prior art keywords
group
preventive
gastric
therapeutic agents
esophageal regurgitation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001230588A
Inventor
Satoshi Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Mitsubishi Tokyo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tokyo Pharmaceuticals Inc filed Critical Mitsubishi Tokyo Pharmaceuticals Inc
Publication of AU2001230588A1 publication Critical patent/AU2001230588A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The compound of the following formula: <CHEM> wherein R<1> and R<2> independently represent a hydrogen atom or a lower alkyl group; A represents a group selected from the group consisting of 1-azabicycloÄ3.2.2Ünonyl group, 1-azabicycloÄ2.2.2Üoctyl group, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof or a hydrate thereof has both improving effect on enterokinetic functions and suppressing effect on acid secretion, and also is highly safe. Accordingly, the substance is useful as preventive or therapeutic medicament for a gastroesophageal reflux disease.
AU2001230588A 2000-02-09 2001-02-07 Preventive or therapeutic agents for gastric or esophageal regurgitation Abandoned AU2001230588A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000031542 2000-02-09
JP2000-31542 2000-02-09
PCT/JP2001/000852 WO2001058898A1 (en) 2000-02-09 2001-02-07 Preventive or therapeutic agents for gastric or esophageal regurgitation

Publications (1)

Publication Number Publication Date
AU2001230588A1 true AU2001230588A1 (en) 2001-08-20

Family

ID=18556282

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001230588A Abandoned AU2001230588A1 (en) 2000-02-09 2001-02-07 Preventive or therapeutic agents for gastric or esophageal regurgitation

Country Status (13)

Country Link
US (7) US6967207B2 (en)
EP (1) EP1256581B1 (en)
JP (1) JP4781592B2 (en)
KR (1) KR100750437B1 (en)
AT (1) ATE358128T1 (en)
AU (1) AU2001230588A1 (en)
CA (1) CA2399818C (en)
DE (1) DE60127535T2 (en)
DK (1) DK1256581T3 (en)
ES (1) ES2284612T3 (en)
PT (1) PT1256581E (en)
TW (1) TWI256314B (en)
WO (1) WO2001058898A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI256314B (en) * 2000-02-09 2006-06-11 Mitsubishi Pharma Corp Preventive-therapeutical medicament for gastroesophageal reflux disease
EP1419772B1 (en) 2001-08-24 2007-07-25 Mitsubishi Pharma Corporation Preventive agent/remedial agent for constipation predominant ibs
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
HUP0402289A2 (en) * 2001-10-02 2005-02-28 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease, pharmaceutical compositions containing them and their use
AR038117A1 (en) 2002-01-14 2004-12-29 Upjohn Co ANTIVIRAL AGENTS DERIVED FROM 4- OXO-4,7 -DIHYDROFIDE [2,3-B] PIRIDIN-5-CARBOXAMIDA
AR038118A1 (en) 2002-01-14 2004-12-29 Upjohn Co COMPOUNDS DERIVED FROM ACID BENCINAMIDE 7-OXO-4,7-DIHIDROTIEN [2,3-B [PIRIDIN-6-CARBOXYLIC 3-REPLACED WHICH ARE USEFUL AS ANTIVIRAL
AR038294A1 (en) * 2002-01-14 2005-01-12 Upjohn Co OXOTIENE (3,2-B) PYRIDINCARBOXAMIDS AS ANTIVIRAL AGENTS
CA2537182A1 (en) * 2003-08-29 2005-03-10 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastrointestinal motility disorders
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
AU2008262438A1 (en) * 2007-06-07 2008-12-18 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastroesophageal reflux disease
MX2012000572A (en) 2009-07-14 2012-05-08 Albany Molecular Res Inc 5-ht3 receptor modulators, methods of making, and use thereof.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829073A (en) * 1988-05-12 1989-05-09 Bristol-Myers Company Thiadiazole oxides for treating gastrointestinal motility disorders
PT95628A (en) * 1989-10-19 1991-09-30 Searle & Co METHOD OF TREATMENT OF GASTROINTESTINAL MOBILITY DISTURBACTIONS WITH ADENOSIN COMPOUND
JP2699794B2 (en) 1992-03-12 1998-01-19 三菱化学株式会社 Thieno [3,2-b] pyridine derivative
SE9603408D0 (en) * 1996-09-18 1996-09-18 Astra Ab Medical use
TWI256314B (en) * 2000-02-09 2006-06-11 Mitsubishi Pharma Corp Preventive-therapeutical medicament for gastroesophageal reflux disease

Also Published As

Publication number Publication date
US20030130304A1 (en) 2003-07-10
CA2399818A1 (en) 2001-08-16
TWI256314B (en) 2006-06-11
EP1256581B1 (en) 2007-03-28
US6967207B2 (en) 2005-11-22
JP4781592B2 (en) 2011-09-28
DE60127535T2 (en) 2007-12-06
DE60127535D1 (en) 2007-05-10
DK1256581T3 (en) 2007-09-24
US20080293762A1 (en) 2008-11-27
CA2399818C (en) 2010-01-12
PT1256581E (en) 2007-06-26
US20100204267A1 (en) 2010-08-12
US20100210679A1 (en) 2010-08-19
EP1256581A4 (en) 2004-10-06
KR100750437B1 (en) 2007-08-21
US20100168157A1 (en) 2010-07-01
US20050282852A1 (en) 2005-12-22
KR20020089340A (en) 2002-11-29
ATE358128T1 (en) 2007-04-15
US20060281781A1 (en) 2006-12-14
WO2001058898A1 (en) 2001-08-16
EP1256581A1 (en) 2002-11-13
ES2284612T3 (en) 2007-11-16

Similar Documents

Publication Publication Date Title
IL205420A (en) Immunoregulatory compounds and derivatives, pharmaceutical compositions and use thereof in treating inflammatory conditions of the gastrointestinal tract
IL148384A0 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
HK1094191A1 (en) Phenyl-carboxamide compounds useful for treating pain
EP1065204A4 (en) Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors
HU0102272D0 (en) Compositions and methods for stimulating gastrointestinal motilis
AU2001230588A1 (en) Preventive or therapeutic agents for gastric or esophageal regurgitation
MXPA02002452A (en) Preventive and therapeutic agents for eye diseases.
WO2003049690A3 (en) Hiv integrase inhibitors
PL359415A1 (en) Oxadiazole derivatives having anticancer effects
HK1045464A1 (en) Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
EP1152004A4 (en) Phosphonic acid derivatives having carboxypeptidase b inhibitory activity
WO2007000392A3 (en) Chloro-substituted guanidines
AU3058501A (en) Pyrrolopyridazine compound
PT1386608E (en) Remedial agent for glomerular disease
AP2002002707A0 (en) 4, 5-Dihydro-Thiazo-2-Ylamine Derivatives and their Use as NO-Synthase Inhibitors.